



VIA REGISTERED POST AND EMAIL

**Attention:** Legal Department  
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.  
No. 1289 Yishan Road  
Shanghai 200233, China  
Email: wangbeining@fosunpharma.com

Date: 11 June 2026

**Re: Mutual Termination of Ensitrelvir Licence Agreement**

Dear Sir/Madam,

We refer to the licence agreement between the Medicines Patent Pool ("**MPP**") and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("**Licensee**") dated 25 June 2023 concerning patents and know-how pertaining to ensitrelvir (the "**Licence Agreement**").

MPP and the Licensee hereby agree to terminate the Licence Agreement with effect from the date of last signature below. This termination is without prejudice to the surviving provisions of the Licence Agreement under Section 12.10.

Please acknowledge your agreement to this termination letter by signing and returning a copy to us.

Sincerely,

**\*\*\* Signature Page to follow\*\*\***



For and on behalf of Medicines  
Patent Pool

A handwritten signature in black ink, appearing to be 'C. Park', written over a horizontal line.

Name: Chan Park  
Title: General Counsel  
Date: 11 June 2026

For and on behalf of Shanghai  
Fosun Pharmaceutical  
Industrial Development Co.,  
Ltd.

A handwritten signature in black ink, appearing to be 'Yuqing Chen', written over a horizontal line.

Name: Yuqing Chen  
Title: Chairman  
Date: 9 September 2026